Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Published online before print November 4, 2009
(Neurology 2009, doi:10.1212/WNL.0b013e3181c51a48)
This Article
Right arrow Full Text (Rapid PDF)
Right arrow Data Supplement
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Schifitto, G.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schifitto, G.
Related Collections
Right arrow MRS
Right arrow HIV
Right arrow All Clinical trials
Right arrow Class II
Right arrow HIV dementia
Received February 17, 2009
Accepted August 3, 2009

Selegiline and oxidative stress in HIV-associated cognitive impairment

G. Schifitto MD*, C. T. Yiannoutsos PhD, T. Ernst PhD, B. A. Navia MD, A. Nath MD, N. Sacktor MD, C. Anderson BSc, C. M. Marra MD, D. B. Clifford MD, For the ACTG 5114 Team

From the University of Rochester (G.S.), NY; Indiana University School of Medicine (C.T.Y.), Indianapolis, IN; John A. Burns School of Medicine (T.E.), University of Hawaii, Honolulu, HI; Tufts Medical School (B.A.N.), Boston, MA; Johns Hopkins University School of Medicine (A.N., N.S., C.A.), Baltimore, MD; Harborview Medical Center (C.M.M.), University of Washington, Seattle, WA; and Washington University School of Medicine (D.B.C.), St. Louis, MO.


* To whom correspondence should be addressed. E-mail: giovanni.schifitto{at}ctcc.rochester.edu.

Objective: To assess the effectiveness of the selegiline transdermal system (STS) in reversing HIV-induced metabolic brain injury (as measured by proton magnetic resonance spectroscopy [MRS]) and in decreasing oxidative stress, measured by CSF protein carbonyl concentration.

Methods: Sixty-two subjects with HIV-associated cognitive impairment were coenrolled in a 24-week placebo-controlled study (AIDS Clinical Trial Group protocol A5090) and were randomly assigned to receive STS 3 mg/24 h, STS 6 mg/24 h, or matching placebo. Cognitive performance was evaluated using the neuropsychological z score (NPZ)-8 and NPZ-6, as well as cognitive domain scores. Subjects underwent proton MRS at study entry and weeks 12 and 24. CSF protein carbonyl was measured at baseline and week 24.

Results: A slight increase in N-acetyl aspartate/creatine from baseline to week 24 was found in the basal ganglia (p = 0.023) and centrum semiovale (p = 0.072) of the placebo group compared with the STS groups; however, there were no significant changes when the absolute metabolite concentrations were analyzed. The levels of choline/creatine in the midfrontal cortex were also significantly higher during the week 12 visit in the combined STS groups. This persisted to the week 24 visit (p = 0.002). Evaluation of the change in NPZ-8, NPZ-6, and cognitive domain scores from baseline to weeks 12 and 24 revealed no significant differences between treatment arms. Protein carbonyl analysis revealed no significant changes among the groups.

Conclusion: In this 24-week study, the selegiline transdermal system (STS) had no effect on either magnetic resonance spectroscopy (MRS) metabolites or oxidative stress, as measured by CSF protein carbonyl concentration. The lack of effect on these biomarkers is also reflected in the lack of cognitive improvement in the STS groups compared to placebo.

Level of evidence: This study provides Class II evidence that STS had no effect on either MRS metabolites or oxidative stress, as measured by CSF protein carbonyl concentration over a period of 24 weeks.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2009 by AAN Enterprises, Inc.